Q3 EPS Estimates for Exact Sciences Cut by Leerink Partnrs

Key Points

• Leerink Partners has revised down its Q3 2025 earnings per share estimate for Exact Sciences to $0.16, from a prior estimate of $0.17.
• Exact Sciences recently reported earnings of $0.22 per share for the previous quarter, significantly beating analysts' consensus estimate of ($0.02) by $0.24.
• The stock has seen significant institutional interest, with 88.82% of shares currently owned by institutional investors, including Vanguard Group and Capital World Investors increasing their stakes.

Exact Sciences Corporation (NASDAQ:EXAS - Free Report) - Stock analysts at Leerink Partnrs cut their Q3 2025 earnings per share estimates for shares of Exact Sciences in a research report issued to clients and investors on Thursday, August 7th. Leerink Partnrs analyst P. Souda now forecasts that the medical research company will post earnings of $0.16 per share for the quarter, down from their prior estimate of $0.17. The consensus estimate for Exact Sciences' current full-year earnings is ($0.58) per share. Leerink Partnrs also issued estimates for Exact Sciences' Q4 2025 earnings at $0.21 EPS, Q1 2026 earnings at $0.17 EPS, Q2 2026 earnings at $0.29 EPS and Q3 2026 earnings at $0.34 EPS.

Exact Sciences (NASDAQ:EXAS - Get Free Report) last announced its earnings results on Wednesday, August 6th. The medical research company reported $0.22 EPS for the quarter, topping the consensus estimate of ($0.02) by $0.24. Exact Sciences had a negative return on equity of 1.75% and a negative net margin of 34.19%. The firm had revenue of $811.09 million for the quarter, compared to analysts' expectations of $774.43 million. During the same quarter in the previous year, the company earned ($0.09) earnings per share. The firm's quarterly revenue was up 16.0% compared to the same quarter last year.

Several other equities analysts have also recently commented on EXAS. Robert W. Baird boosted their price target on shares of Exact Sciences from $69.00 to $72.00 and gave the company an "outperform" rating in a report on Friday, May 2nd. Evercore ISI lowered their price target on shares of Exact Sciences from $68.00 to $64.00 and set an "outperform" rating on the stock in a report on Friday. Piper Sandler lowered their price target on shares of Exact Sciences from $70.00 to $60.00 and set an "overweight" rating on the stock in a report on Monday. Barclays decreased their price objective on shares of Exact Sciences from $65.00 to $55.00 and set an "overweight" rating for the company in a report on Thursday, August 7th. Finally, Royal Bank Of Canada lowered their target price on shares of Exact Sciences from $54.00 to $46.00 and set a "sector perform" rating on the stock in a research report on Thursday, August 7th. Three equities research analysts have rated the stock with a hold rating, twenty-one have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $67.43.

Exact Sciences Price Performance

Shares of NASDAQ EXAS traded up $0.67 during trading on Friday, hitting $41.58. The company had a trading volume of 2,153,706 shares, compared to its average volume of 2,754,910. The business's 50-day moving average is $51.25 and its 200 day moving average is $49.89. The company has a debt-to-equity ratio of 0.94, a quick ratio of 2.56 and a current ratio of 2.89. Exact Sciences has a 52 week low of $38.81 and a 52 week high of $72.83. The company has a market cap of $7.87 billion, a P/E ratio of -7.66, a PEG ratio of 4.74 and a beta of 0.93.

Insider Buying and Selling at Exact Sciences

In related news, Director Katherine S. Zanotti sold 3,207 shares of the stock in a transaction dated Friday, June 13th. The shares were sold at an average price of $53.20, for a total value of $170,612.40. Following the completion of the sale, the director owned 72,759 shares in the company, valued at approximately $3,870,778.80. This trade represents a 4.22% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 1.20% of the company's stock.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in EXAS. Bank Pictet & Cie Europe AG raised its position in Exact Sciences by 1.2% in the fourth quarter. Bank Pictet & Cie Europe AG now owns 129,024 shares of the medical research company's stock worth $7,250,000 after purchasing an additional 1,547 shares in the last quarter. Resona Asset Management Co. Ltd. acquired a new position in Exact Sciences in the fourth quarter worth about $3,031,000. Aviva PLC acquired a new position in Exact Sciences in the fourth quarter worth about $5,824,000. Cerity Partners LLC increased its holdings in shares of Exact Sciences by 65.9% during the fourth quarter. Cerity Partners LLC now owns 27,090 shares of the medical research company's stock worth $1,541,000 after buying an additional 10,761 shares in the last quarter. Finally, Invesco Ltd. increased its holdings in shares of Exact Sciences by 57.2% during the fourth quarter. Invesco Ltd. now owns 379,683 shares of the medical research company's stock worth $21,334,000 after buying an additional 138,089 shares in the last quarter. Institutional investors and hedge funds own 88.82% of the company's stock.

About Exact Sciences

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.